Pharmacogenomic Implications of Population Admixture: Brazil as a Model Case

• Callegari-Jacques SM , SalzanoFM. Brazilian Indian/non Indian interactions and their effects. Cienc. Cult.51(3–4) , 166–174 (1999).
   Google Scholar
• Suarez-Kurtz G , PenaSDJ. Pharmacogenetic studies in the Brazilian population. In: Pharmacogenomics in Admixed Populations. Suarez-Kurtz G (Ed.). Landes Biosciences, Austin, TX, USA, 75–98 (2007).
   Google Scholar
• Suarez-Kurtz G . Pharmacogenomic applications in the developing world: the American continent. In: Genomics Applications for the Developing World. Nelson KE, Jones-Nelson B (Eds). Springer, Heidelberg, Germany, 147–160 (2012).
   Google Scholar
• Suarez-Kurtz G , PenaSDJ, StruchinerCJ, HutzMH. Pharmacogenomic diversity among Brazilians: influence of diversity, self reported color and geographical origin. Front. Pharmacol.3 , 191 (2012).
   PubMed Web of Science ®Google Scholar
• Bastos-Rodrigues L , PimentaJR, PenaSDJ. The genetic structure of human populations studied through short insertion–deletion polymorphisms. Ann. Hum. Genet.70(5) , 658–665 (2006).
   Google Scholar
• Salzano FM , BortoliniMC. The Evolution and Genetics of Latin American Populations. Cambridge University Press, Cambridge, UK (2002).
   Google Scholar
• Parra FC , AmadoRC, LambertucciJR, RochaJ, AntunesCM, PenaSDJ. Color and genomic ancestry in Brazilians. Proc. Natl Acad. Sci. USA100(1) , 177–182 (2003).
   PubMed Web of Science ®Google Scholar
• Pena SDJ , Di-PietroG, Fuchshuber-MoraesM et al. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS ONE 6(2) , e17063 (2011).
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G . Pharmacogenetics in the Brazilian population. Front. Pharmacol.1(118) , 1–10 (2010).
   PubMedGoogle Scholar
• Suarez-Kurtz G , VargensDD, StruchinerCJ, Bastos-RodriguesL, PenaSDJ. Self-reported skin color, genomic ancestry and the distribution of GST polymorphisms. Pharmacogenet. Genomics17(9) , 765–771 (2007).
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G , PeriniJA, Bastos-RodriguesL, PenaSD, StruchinerC. Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics8 , 1299–1306 (2007).
   PubMed Web of Science ®Google Scholar
• Estrela RC , RibeiroFS, CarvalhoRS et al. Distribution of ABCB1 polymorphisms among Brazilians: impact of population admixture. Pharmacogenomics 9 , 267–276 (2008).
   PubMed Web of Science ®Google Scholar
• Vargens DD , AlmendraL, StruchinerCJ, Suarez-KurtzG. Distribution of the GNB3 825C>T polymorphism among Brazilians: impact of population structure. Eur. J. Clin. Pharmacol.3 , 253–256 (2008).
   Google Scholar
• Suarez-Kurtz G , AmorimA, DamascenoA et al. VKORC1 polymorphisms in Brazilians, comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications. Pharmacogenomics11 , 1257–1267 (2010).
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G , GenroJP, MoraesMO et al. Global pharmacogenomics: impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. Pharmacogenomics J. 12 , 267–276 (2012).
   PubMed Web of Science ®Google Scholar
• Perini JA , Petzl-ErlerML, TsunetoLT, Suarez-KurtzG. VKORC1 polymorphisms in Amerindian populations of Brazil. Pharmacogenomics9 , 1623–1629 (2008).
   PubMed Web of Science ®Google Scholar
• Vargens DD , DamascenoA, Petzl-ErlerML, Suarez-KurtzG. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among Amerindians, Mozambicans and Brazilians. Pharmacogenomics12 , 769–772 (2011).
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G , PenaSD, HutzMH. Application of the F(ST) statistics to explore pharmacogenomic diversity in the Brazilian population. Pharmacogenomics13 , 771–777 (2012).
   PubMed Web of Science ®Google Scholar
• Wright S . The genetic structure of populations. Ann. Eugen.15 , 323–3543 (1951).
   PubMedGoogle Scholar
• Wright S . Variability Within and Among Natural Populations. University of Chicago Press, IL, USA, 4 (1978).
   Google Scholar
• Estrela RC , SantoroAB, BarrosoPF, TuyamaM, Suarez-KurtzG. CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects. Clin. Pharmacol. Ther.84 , 205–207 (2008).
   PubMed Web of Science ®Google Scholar
• Kohlrausch FB , Salatino-OliveiraA, GamaCS, LobatoMI, Belmonte-de-AbreuP, HutzMH. G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics. Pharmacogenomics9 , 1429–1436 (2008).
   PubMed Web of Science ®Google Scholar
• Perini JA , StruchinerCJ, Silva-AssuncaoE et al. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin. Pharmacol. Ther. 84 , 722–728 (2008).
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G , PeriniJA, Silva-AssuncaoE, StruchinerCJ. Relative contribution of VKORC1, CYP2C9 and INR response to warfarin stable dose. Blood113 , 4125–4126 (2009).
   PubMed Web of Science ®Google Scholar
• Perini JA , StruchinerCJ, Silva-AssuncaoE, Suarez-KurtzG. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin. Pharmacol. Ther.87 , 417–420 (2010).
   PubMed Web of Science ®Google Scholar
• Gage BF , EbyC, JohnsonJA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84 , 326–331 (2008).
   PubMed Web of Science ®Google Scholar
• International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med.360(8) , 753–764 (2009). Erratum in: N. Engl. J. Med.361(16) , 1613 (2009).
   PubMed Web of Science ®Google Scholar
• Limdi NA , WadeliusM, CavallariL et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across three racial groups. Blood 115 , 3827–3834 (2010).
   PubMed Web of Science ®Google Scholar
• Botton M , BandinelliE, RohdeL, AmonL, HutzM. Influence of genetic, biological and pharmacological factors on warfarin dose in a southern Brazilian population of European ancestry. Br. J. Clin. Pharmacol.72(3) , 442–450 (2011).
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G . Population diversity and the performance of warfarin dosing algorithms. Br. J. Clin. Pharmacol.72 , 451–453 (2011).
   PubMed Web of Science ®Google Scholar
• Staatz CE , GoodmanLK, TettSE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin. Pharmacokinet.49 , 141–175 (2010).
   PubMed Web of Science ®Google Scholar
• Tavira B , CotoE, Diaz-CorteC et al. Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clin. Chem. Lab. Med. 49 , 825–833 (2011).
   PubMed Web of Science ®Google Scholar
• Elens L , BouamarR, HesselinkDA et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 57 , 1574–1583 (2011).
   PubMed Web of Science ®Google Scholar
• de Jonge H , de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR. In vivoCYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin. Pharmacol. Ther.92 , 366–375 (2012).
   PubMed Web of Science ®Google Scholar
• Santoro A , FelipeCR, Tedesco-SilvaH et al. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics 12 , 1293–1303 (2011).
   PubMed Web of Science ®Google Scholar
• Santoro AB , StruchinerCJ, FelipeCR et al. CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients. Clin. Pharmacol. Ther.94(2) , 201–202 (2013).
   PubMed Web of Science ®Google Scholar
• van Gelder T , van Schaik RH, Hesselink DA. Practicability of pharmacogenetics in transplantation medicine. Clin. Pharmacol. Ther. doi:10.1038/clpt.2013.169 (2013) (Epub ahead of print).
   Google Scholar
• Johnson EG , HorneBD, CarlquistJF, AndersonJL. Genotype-based dosing algorithms for warfarin therapy: data review and recommendations. Mol. Diagn. Ther.15(5) , 255–264 (2011).
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G . Pharmacogenetics in admixed populations. Trends Pharmacol. Sci.26(4) , 196–201 (2005).
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G (Ed.). Pharmacogenomics in Admixed Populations. Landes Biosciences, Austin, TX, USA (2007).
   Google Scholar

▪ Websites

• Countries ranked by Gross Domestic Product. http://en.wikipedia.org/wiki/List_of_countries_by_GDP_(nominal)
   Google Scholar
• The Human Development Index used by the United Nations Development Program to rank countries. http://en.wikipedia.org/wiki/Human_Development_Index
   Google Scholar
• Home Page of the Instituto Brasileiro de Geografia e Estatística (IBGE), responsible for the Brazilian Census. www.ibge.gov.br
   Google Scholar
• Brazilian Pharmacogenomics Network, Refargen. www.refargen.org.br
   Google Scholar
• Refargen database of pharmacogenomic polymorphisms in Brazilians. www.refargen.org.br/rubrique.php3?id_rubrique=28
   Google Scholar
• Pharmacogenomics Knowledge Base (PharmGKB): Browse Annotated PGx Genes. www.pharmgkb.org/search/browseVip.action?browseKey=annotatedGenes
   Google Scholar
• International HapMap project. http://hapmap.ncbi.nlm.nih.gov
   Google Scholar